Invikafusp alfa
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Invikafusp alfa, covering 2025-09-24 to 2025-09-24. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors [Phase 1, Phase 2]